For tumors with a low pretest probability of a positive result (e.g., breast cancers in general), a cancer gene panel would be a better test to exclude other more common targetable molecular alterations (Fig. 2). Treatment of MBC harboring NTRK fusions with TRK inhibitors is approved for ...
Many of the recent advances in immuno-oncology have involved checkpoint inhibitors, including the breakthrough PD-1 inhibitors pembrolizumab (Keytruda®) and nivolumab (Opdivo), as well as PD-L1 and CTLA-4 inhibitors. This antibody-based therapy binds to immune-checkpoint proteins expressed on ...